Scanned by

    Norton

    Norton™ Safe Web

    Novartis – Who We Are

    Novartis – Who We Are

    00:52 |
    Download Here

    You Might Also Like:

    Novartis mission

    Novartis mission

    1:16 |
    Novartis CEO: Our leukemia drug Scemblix is a potential $3 billion plus medicine

    Novartis CEO: Our leukemia drug Scemblix is a potential $3 billion plus medicine

    4:43 |
    Novartis CEO discusses how AI will impact drug development

    Novartis CEO discusses how AI will impact drug development

    6:51 |
    Novartis, Sandoz recall 12 medications over packaging concerns

    Novartis, Sandoz recall 12 medications over packaging concerns

    0:34 |
    Novartis – Who We Are

    Novartis – Who We Are

    0:52 |
    Novartis CEO Vas Narasimhan on The David Rubenstein Show

    Novartis CEO Vas Narasimhan on The David Rubenstein Show

    24:07 |
    Novartis as a focused innovative medicines company

    Novartis as a focused innovative medicines company

    0:54 |
    25 Years of Novartis – Continuing our innovation journey

    25 Years of Novartis – Continuing our innovation journey

    2:59 |
    Amy C. Edmondson - The Science of Failing Well #GLS24

    Amy C. Edmondson - The Science of Failing Well #GLS24

    1:00 |
    Novartis not joining the 'frenzy' of weight loss drugs, CEO says

    Novartis not joining the 'frenzy' of weight loss drugs, CEO says

    3:45 |
    Novartis CEO on Acquisitions, AI, Weight-Loss Drugs

    Novartis CEO on Acquisitions, AI, Weight-Loss Drugs

    4:19 |
    Novartis Raises Outlook After Sandoz Generics Spinoff

    Novartis Raises Outlook After Sandoz Generics Spinoff

    1:58 |
    Novartis CEO Vas Narasimhan on the latest research on a breast cancer drug

    Novartis CEO Vas Narasimhan on the latest research on a breast cancer drug

    3:43 |
    Research and Development: It’s our heartbeat.

    Research and Development: It’s our heartbeat.

    1:12 |
    Manufacturing CAR-T Cell Therapies: The Novartis Approach

    Manufacturing CAR-T Cell Therapies: The Novartis Approach

    2:14 |
    Pokert Novartis auf Kosten der Patienten? Wenn Krebstherapien unbezahlbar werden | Doku | SRF Dok

    Pokert Novartis auf Kosten der Patienten? Wenn Krebstherapien unbezahlbar werden | Doku | SRF Dok

    51:16 |
    Novartis Cancer Drug Is Approved With $475,000 Price Tag

    Novartis Cancer Drug Is Approved With $475,000 Price Tag

    1:13 |
    Novartis Ruxolitinib Gets CDSCO Panel Nod For Acute And Chronic Graft Versus Host Disease

    Novartis Ruxolitinib Gets CDSCO Panel Nod For Acute And Chronic Graft Versus Host Disease

    1:52 |
    Novartis - History and Company profile (overview)

    Novartis - History and Company profile (overview)

    2:36 |
    South Asian Trailblazers: Vas Narasimhan (CEO of Novartis) and Srishti Gupta (Leader in Health & Ed)

    South Asian Trailblazers: Vas Narasimhan (CEO of Novartis) and Srishti Gupta (Leader in Health & Ed)

    1:14:03 |